Atossa Therapeutics Inc [NASDAQ: ATOS] jumped around 0.09 points on Tuesday, while shares priced at $1.84 at the close of the session, up 5.14%. The company report on April 9, 2024 at 11:59 AM that Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen.
The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study. Seven women were enrolled in the cohort and treated daily for 28 days. At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months. Per the study protocol, the seventh patient, whose Ki-67 decreased 19% but stayed above 10%, discontinued treatment and had surgery.
Compared to the average trading volume of 1.37M shares, ATOS reached a trading volume of 3843714 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Atossa Therapeutics Inc [ATOS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATOS shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATOS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Atossa Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc is set at 0.22 The Price to Book ratio for the last quarter was 2.53, with the Price to Cash per share for the same quarter was set at 0.71.
How has ATOS stock performed recently?
Atossa Therapeutics Inc [ATOS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by 0.00. With this latest performance, ATOS shares gained by 68.81% in over the last four-week period, additionally plugging by 153.97% over the last 6 months – not to mention a rise of 154.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 59.64, with the RSI for the last a single of trading hit 55.89, and the three-weeks RSI is set at 61.65 for Atossa Therapeutics Inc [ATOS]. The present Moving Average for the last 50 days of trading for this stock 1.2610, while it was recorded at 1.9170 for the last single week of trading, and 0.9569 for the last 200 days.
Atossa Therapeutics Inc [ATOS]: Deeper insight into the fundamentals
Atossa Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.61 and a Current Ratio set at 17.61.
Earnings analysis for Atossa Therapeutics Inc [ATOS]
With the latest financial reports released by the company, Atossa Therapeutics Inc posted -0.05/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 16.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATOS.
Insider trade positions for Atossa Therapeutics Inc [ATOS]
The top three institutional holders of ATOS stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in ATOS stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in ATOS stock with ownership which is approximately 5.8386%.
